Hardman & Co Research: Advanced Oncotherapy (AVO): Commercialising a breakthrough technology

Hardman & Co Research 
Hardman & Co Research: Advanced Oncotherapy (AVO): Commercialising a 
breakthrough technology 
 
13-May-2019 / 12:20 GMT/BST 
 
*Hardman & Co: Commercialising a breakthrough technology* 
 
Advanced Oncotherapy's (AVO) goal is to deliver an affordable and novel proton 
beam therapy (PBT) system, based on state-of-the-art technology developed 
originally at the world-renowned CERN. 2018 was characterised by achievement 
of a number of technical milestones, the successful integration of all the 
module types that constitute the LIGHT accelerator, and acceleration of the 
proton beam to an energy of 52MeV, sufficient to treat superficial tumours. 
With LIGHT, its breakthrough PBT technology, AVO is aiming to replicate the 
commercial success of MRI by opening new untapped markets with an innovative 
financing strategy. 
 
Please click here for the full report: 
 
https://www.hardmanandco.com/research/corporate-research/commercialising-a-bre 
akthrough-technology/ [1] 
 
+------------------------+----------------+--------------------+ 
|*To contact us:*        |*Contacts:*     |                    | 
|                        |                |[e-mail] | 
|Hardman & Co            |Dr Martin Hall  |[e-mail]| 
|35 New Broad Street     |Dr Dorothea Hill|[e-mail] | 
|London                  |Dr Gregoire Pave|                    | 
|EC2M 1NH                |                |                    | 
|www.hardmanandco.com    |[phone]|                    | 
|*Follow us on Twitter*  |                |                    | 
|@HardmanandCo           |                |                    | 
+------------------------+----------------+--------------------+ 
 
*Hardman & Co Research can still be accessed for free after MiFID II. Please 
*click here [2] *to read the statement.* 
 
*About Hardman & Co:* For the past 21 years Hardman has been producing 
specialist research designed to improve investors' understanding of companies, 
sectors, industries and investment securities. Our analysts are highly 
experienced in their sectors, and have often been highly rated by professional 
investors for their knowledge. Our focus is to raise companies' profiles 
across the world with high-quality research, investor engagement programmes 
and advisory services. 
 
Hardman Research Ltd, trading as Hardman & Co, is an appointed representative 
of Capital Markets Strategy Ltd and is authorised and regulated by the 
Financial Conduct Authority; our FCA registration number is 600843. Hardman 
Research Ltd is registered at Companies House with number 8256259. 
 
Our research is provided for the use of the professional investment community, 
market counterparties and sophisticated and high net worth investors as 
defined in the rules of the regulatory bodies. It is not intended to be made 
available to unsophisticated retail investors. Anyone who is unsure of their 
categorisation should consult their professional advisors. This research is 
neither an offer, nor a solicitation, to buy or sell any security. Please read 
the note for the full disclaimer. 
 
Dissemination of a CORPORATE NEWS, transmitted by EQS Group. 
The issuer is solely responsible for the content of this announcement. 
End of Announcement - EQS News Service 
 
810373 13-May-2019 
 
 
1: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=6b8d737b6e8f982b7c9cd715d7f1ac10&application_id=810373&site_id=vwd&application_name=news 
2: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=5a632f52f80bd372265e4041a743aa1c&application_id=810373&site_id=vwd&application_name=news 
 

(END) Dow Jones Newswires

May 13, 2019 07:20 ET (11:20 GMT)